Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors

Biochimie

Volumn 105, Issue , 2014, Pages 4-11

  Amara, Ikrame ^a   Touati, Walid ^a   Beaune, Philippe ^a   De Waziers, Isabelle ^a  

^a INSERM   (France)

Author keywords

Cancer; Mesenchymal stem cells; Suicide gene therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOSINE DEAMINASE; ENZYME; FIRTECAN; FLUCYTOSINE; GANCICLOVIR; THYMIDINE KINASE; DRUG VEHICLE; PRODRUG;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAST CANCER; BYSTANDER EFFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELL ENGINEERING; DRUG CYTOTOXICITY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; KIDNEY TUMOR; LIVER CELL CARCINOMA; LUNG METASTASIS; MESENCHYMAL STEM CELL; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY TUMOR; PANCREAS TUMOR; PROSTATE CANCER; REVIEW; STEM CELL GENE THERAPY; SUICIDE GENE; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; GENE THERAPY; GENE TRANSFER; GENETICS; MESENCHYMAL STROMA CELL; NEOPLASMS; PATHOLOGY; SUICIDE TRANSGENE;

GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASMS; PHARMACEUTICAL VEHICLES; PRODRUGS;

EID: 84907818277     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.06.016     Document Type: Review

References (98)

1. O. Greco, and G.U. Dachs Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives J. Cell. Physiology 187 2001 22 36
2. W. Touati, P. Beaune, and I. de Waziers Cancer gene therapy: the new targeting challenge Oner Ozdemir, Current Cancer Treatment - Novel Beyond Conventional Approaches 2011 InTech 978-953-307-397-2 10.5772/24788 Available from: http://www.intechopen.com/books/current-cancer-treatment-novel-beyond-conventional-approaches/cancer-gene-therapy-the-new-targeting-challenge
3. W.L. Bi, L.M. Parysek, R. Warnick, and P.J. Stambrook In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy Hum. Gene Ther. 4 1993 725 731
4. S. Gagandeep, R. Brew, B. Green, S.E. Christmas, D. Klatzmann, G.J. Poston, and A.R. Kinsella Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect" Cancer Gene Ther. 3 1996 83 88
5. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel Immunogenic cell death in cancer therapy Annu Rev. Immunol. 31 2013 51 72
6. S. Kuriyama, H. Tsujinoue, and H. Yoshiji Immune response to suicide gene therapy Methods Mol. Med. 90 2004 353 369
7. W. Touati, T. Tran, J. Seguin, M. Diry, F. Jean-Pierre, C. Baillou, G. Lescaille, F. Andre, E. Tartour, F.M. Lemoine, P. Beaune, and I. de Waziers A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response Curr. gene Ther. 2014
8. A.A. Elshami, A. Saavedra, H. Zhang, J.C. Kucharczuk, D.C. Spray, G.I. Fishman, K.M. Amin, L.R. Kaiser, and S.M. Albelda Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Ther. 3 1996 85 92
9. C. Fillat, M. Carrio, A. Cascante, and B. Sangro Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application Curr. Gene Ther. 3 2003 13 26
10. R.G. Crystal, E. Hirschowitz, M. Lieberman, J. Daly, E. Kazam, C. Henschke, D. Yankelevitz, N. Kemeny, R. Silverstein, A. Ohwada, T. Russi, A. Mastrangeli, A. Sanders, J. Cooke, and B.G. Harvey Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine Hum. Gene Ther. 8 1997 985 1001
11. I. King, D. Bermudes, S. Lin, M. Belcourt, J. Pike, K. Troy, T. Le, M. Ittensohn, J. Mao, W. Lang, J.D. Runyan, X. Luo, Z. Li, and L.M. Zheng Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent Hum. Gene Ther. 13 2002 1225 1233
12. T. Satoh, M. Hosokawa, R. Atsumi, W. Suzuki, H. Hakusui, and E. Nagai Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase Biol. Pharm. Bull. 17 1994 662 664
13. M. Wierdl, C.L. Morton, J.K. Weeks, M.K. Danks, L.C. Harris, and P.M. Potter Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase Cancer Res. 61 2001 5078 5082
14. M.X. Wei, T. Tamiya, M. Chase, E.J. Boviatsis, T.K. Chang, N.W. Kowall, F.H. Hochberg, D.J. Waxman, X.O. Breakefield, and E.A. Chiocca Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene Hum. Gene Ther. 5 1994 969 978
15. L. Chen, and D.J. Waxman Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy Cancer Res. 55 1995 581 589
16. T.A. Nguyen, M. Tychopoulos, F. Bichat, C. Zimmermann, J.P. Flinois, M. Diry, E. Ahlberg, M. Delaforge, L. Corcos, P. Beaune, P. Dansette, F. Andre, and I. de Waziers Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo Mol. Pharmacol. 73 2008 1122 1133
17. J.P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M.D. Forster, R. Gibson, A. Makris, D.C. Talbot, J. Steiner, L. White, O. Kan, S. Naylor, M.W. Carroll, S.M. Kingsman, and A.L. Harris Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma Clin. Cancer Res. 11 2005 1512 1520
18. F. Xu, S. Li, X.L. Li, Y. Guo, B.Y. Zou, R. Xu, H. Liao, H.Y. Zhao, Y. Zhang, Z.Z. Guan, and L. Zhang Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors Cancer Gene Ther. 16 2009 723 730
19. N. Kim, and S.G. Cho Clinical applications of mesenchymal stem cells Korean J. Intern Med. 28 2013 387 402
20. H. Kosaka, T. Ichikawa, K. Kurozumi, H. Kambara, S. Inoue, T. Maruo, K. Nakamura, H. Hamada, and I. Date Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma Cancer Gene Ther. 19 2012 572 578
21. M. Studeny, F.C. Marini, R.E. Champlin, C. Zompetta, I.J. Fidler, and M. Andreeff Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors Cancer Res. 62 2002 3603 3608
22. D. Bexell, S. Gunnarsson, A. Tormin, A. Darabi, D. Gisselsson, L. Roybon, S. Scheding, and J. Bengzon Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas Mol. Ther. 17 2009 183 190
23. S. Kidd, L. Caldwell, M. Dietrich, I. Samudio, E.L. Spaeth, K. Watson, Y. Shi, J. Abbruzzese, M. Konopleva, M. Andreeff, and F.C. Marini Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment Cytotherapy 12 2010 615 625
24. E. Spaeth, A. Klopp, J. Dembinski, M. Andreeff, and F. Marini Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells Gene Ther. 15 2008 730 738
25. P. Bourin, B.A. Bunnell, L. Casteilla, M. Dominici, A.J. Katz, K.L. March, H. Redl, J.P. Rubin, K. Yoshimura, and J.M. Gimble Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) Cytotherapy 15 2013 641 648
26. K.S. Aboody, A. Brown, N.G. Rainov, K.A. Bower, S. Liu, W. Yang, J.E. Small, U. Herrlinger, V. Ourednik, P.M. Black, X.O. Breakefield, and E.Y. Snyder Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas Proc. Natl. Acad. Sci. U. S. A. 97 2000 12846 12851
27. L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy Cancer Res. 67 2007 6304 6313
28. M.D. Griffin, T. Ritter, and B.P. Mahon Immunological aspects of allogeneic mesenchymal stem cell therapies Hum. Gene Ther. 21 2010 1641 1655
29. J. Stagg, S. Pommey, N. Eliopoulos, and J. Galipeau Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell Blood 107 2006 2570 2577
30. J.L. Chan, K.C. Tang, A.P. Patel, L.M. Bonilla, N. Pierobon, N.M. Ponzio, and P. Rameshwar Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma Blood 107 2006 4817 4824
31. N. Eliopoulos, J. Stagg, L. Lejeune, S. Pommey, and J. Galipeau Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice Blood 106 2005 4057 4065
32. M. Francois, R. Romieu-Mourez, S. Stock-Martineau, M.N. Boivin, J.L. Bramson, and J. Galipeau Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties Blood 114 2009 2632 2638
33. R. Romieu-Mourez, M. Francois, M.N. Boivin, J. Stagg, and J. Galipeau Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density J. Immunol. 179 2007 1549 1558
34. M. Aghi, F. Hochberg, and X.O. Breakefield Prodrug activation enzymes in cancer gene therapy J. Gene Med. 2 2000 148 164
35. X.Y. Bak, J. Yang, and S. Wang Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy Cancer Gene Ther. 17 2010 721 729
36. C. Conrad, Y. Husemann, H. Niess, I. von Luettichau, R. Huss, C. Bauer, K.W. Jauch, C.A. Klein, C. Bruns, and P.J. Nelson Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis Ann. Surg. 253 2011 566 571
37. S.W. Kim, S.J. Kim, S.H. Park, H.G. Yang, M.C. Kang, Y.W. Choi, S.M. Kim, S.S. Jeun, and Y.C. Sung Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK Clin. Cancer Res. 19 2013 415 427
38. S. Li, C. Gu, Y. Gao, S. Amano, S. Koizumi, T. Tokuyama, and H. Namba Bystander effect in glioma suicide gene therapy using bone marrow stromal cells Stem Cell Res. 9 2012 270 276
39. M. Matuskova, K. Hlubinova, A. Pastorakova, L. Hunakova, V. Altanerova, C. Altaner, and L. Kucerova HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells Cancer Lett. 290 2010 58 67
40. H. Niess, Q. Bao, C. Conrad, C. Zischek, M. Notohamiprodjo, F. Schwab, B. Schwarz, R. Huss, K.W. Jauch, P.J. Nelson, and C.J. Bruns Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma Ann. Surg. 254 2011 767 774 discussion 774-765
41. C.H. Ryu, K.Y. Park, S.M. Kim, C.H. Jeong, J.S. Woo, Y. Hou, and S.S. Jeun Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma Biochem. Biophys. Res. Commun. 421 2012 585 590
42. T.Y. Zhang, B. Huang, Z.Y. Yuan, Y.L. Hu, Y. Tabata, and J.Q. Gao Gene recombinant bone marrow mesenchymal stem cells as a tumor-targeted suicide gene delivery vehicle in pulmonary metastasis therapy using non-viral transfection Nanomedicine 10 2014 257 267
43. C. Zischek, H. Niess, I. Ischenko, C. Conrad, R. Huss, K.W. Jauch, P.J. Nelson, and C. Bruns Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma Ann. Surg. 250 2009 747 753
44. H.M. Amm, T. Zhou, A.D. Steg, H. Kuo, Y. Li, and D.J. Buchsbaum Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells Mol. Cancer Res. 9 2011 403 417
45. C. Beltinger, S. Fulda, H. Walczak, and K.M. Debatin TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells Cancer Gene Ther. 9 2002 372 381
46. R. Uchibori, T. Okada, T. Ito, M. Urabe, H. Mizukami, A. Kume, and K. Ozawa Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy J. Gene Med. 11 2009 373 381
47. T. Ichikawa, T. Tamiya, Y. Adachi, Y. Ono, K. Matsumoto, T. Furuta, Y. Yoshida, H. Hamada, and T. Ohmoto In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus Cancer Gene Ther. 7 2000 74 82
48. P. Gopinath, and S.S. Ghosh Implication of functional activity for determining therapeutic efficacy of suicide genes in vitro Biotechnol. Lett. 30 2008 1913 1921
49. H. Kato, K. Koshida, K. Yokoyama, A. Mizokami, and M. Namiki Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study Int. J. Urol. 9 2002 567 576
50. M. Chaszczewska-Markowska, K. Stebelska, A. Sikorski, J. Madej, A. Opolski, and M. Ugorski Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase - for colorectal cancer Cancer Lett. 262 2008 164 172
51. E.A. Hirschowitz, A. Ohwada, W.R. Pascal, T.J. Russi, and R.G. Crystal In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine Hum. Gene Ther. 6 1995 1055 1063
52. N.N. Hanna, H.J. Mauceri, J.D. Wayne, D.E. Hallahan, D.W. Kufe, and R.R. Weichselbaum Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts Cancer Res. 57 1997 4205 4209
53. M.H. You, W.J. Kim, W. Shim, S.R. Lee, G. Lee, S. Choi, D.Y. Kim, Y.M. Kim, H. Kim, and S.U. Han Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model J. Gastroenterol. Hepatol. 24 2009 1393 1400
54. E. Kievit, M.K. Nyati, E. Ng, L.D. Stegman, J. Parsels, B.D. Ross, A. Rehemtulla, and T.S. Lawrence Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts Cancer Res. 60 2000 6649 6655
55. P. Erbs, E. Regulier, J. Kintz, P. Leroy, Y. Poitevin, F. Exinger, R. Jund, and M. Mehtali In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene Cancer Res. 60 2000 3813 3822
56. A. Khatri, B. Zhang, E. Doherty, J. Chapman, K. Ow, H. Pwint, R. Martiniello-Wilks, and P.J. Russell Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice J. Gene Med. 8 2006 1086 1096
57. M. Ramnaraine, W. Pan, M. Goblirsch, C. Lynch, V. Lewis, P. Orchard, P. Mantyh, and D.R. Clohisy Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene Cancer Res. 63 2003 6847 6854
58. D.Z. Shi, W.X. Hu, L.X. Li, G. Chen, D. Wei, and P.Y. Gu Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma Chin. Med. J. (Engl.) 122 2009 1267 1272
59. L. Kucerova, M. Matuskova, A. Pastorakova, S. Tyciakova, J. Jakubikova, R. Bohovic, V. Altanerova, and C. Altaner Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice J. Gene Med. 10 2008 1071 1082
60. I.T. Cavarretta, V. Altanerova, M. Matuskova, L. Kucerova, Z. Culig, and C. Altaner Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth Mol. Ther. 18 2010 223 231
61. V. Altanerova, M. Cihova, M. Babic, B. Rychly, K. Ondicova, B. Mravec, and C. Altaner Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma Int. J. Cancer 130 2012 2455 2463
62. C. Altaner, V. Altanerova, M. Cihova, K. Ondicova, B. Rychly, L. Baciak, and B. Mravec Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario Int. J. Cancer 134 2014 1458 1465
63. M.K. Danks, K.J. Yoon, R.A. Bush, J.S. Remack, M. Wierdl, L. Tsurkan, S.U. Kim, E. Garcia, M.Z. Metz, J. Najbauer, P.M. Potter, and K.S. Aboody Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma Cancer Res. 67 2007 22 25
64. S.A. Choi, J.Y. Lee, K.C. Wang, J.H. Phi, S.H. Song, J. Song, and S.K. Kim Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas Eur. J. Cancer 48 2012 129 137
65. G.I. Jallo, A. Volkov, C. Wong, B.S. Carson Sr., and M.B. Penno A novel brainstem tumor model: functional and histopathological characterization Childs Nerv. Syst. 22 2006 1519 1525
66. M.D. Prados, K. Lamborn, W.K. Yung, K. Jaeckle, H.I. Robins, M. Mehta, H.A. Fine, P.Y. Wen, T. Cloughesy, S. Chang, M.K. Nicholas, D. Schiff, H. Greenberg, L. Junck, K. Fink, K. Hess, and J. Kuhn A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro-Oncology 8 2006 189 193
67. L. Gervot, B. Rochat, J.C. Gautier, F. Bohnenstengel, H. Kroemer, V. de Berardinis, H. Martin, P. Beaune, and I. de Waziers Human CYP2B6: expression, inducibility and catalytic activities Pharmacogenetics 9 1999 295 306
68. P.S. Schwartz, and D.J. Waxman Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells Mol. Pharmacol. 60 2001 1268 1279
69. M. Tychopoulos, L. Corcos, P. Genne, P. Beaune, and I. de Waziers A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein Cancer Gene Ther. 12 2005 497 508
70. A. Lorico, J. Mercapide, V. Solodushko, M. Alexeyev, O. Fodstad, and G. Rappa Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma Cancer Gene Ther. 15 2008 605 615
71. J. Mercapide, G. Rappa, F. Anzanello, J. King, O. Fodstad, and A. Lorico Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma Int. J. Cancer 126 2010 1206 1215
72. M. Studeny, F.C. Marini, J.L. Dembinski, C. Zompetta, M. Cabreira-Hansen, B.N. Bekele, R.E. Champlin, and M. Andreeff Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents J. Natl. Cancer Inst. 96 2004 1593 1603
73. W. Zou, H. Zheng, T.C. He, J. Chang, Y.X. Fu, and W. Fan LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response Cancer Res. 72 2012 2980 2989
74. P. Gao, Q. Ding, Z. Wu, H. Jiang, and Z. Fang Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma Cancer Lett. 290 2010 157 166
75. T.E. Meyerrose, D.A. De Ugarte, A.A. Hofling, P.E. Herrbrich, T.D. Cordonnier, L.D. Shultz, J.C. Eagon, L. Wirthlin, M.S. Sands, M.A. Hedrick, and J.A. Nolta In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models Stem Cells 25 2007 220 227
76. K. Morizono, D.A. De Ugarte, M. Zhu, P. Zuk, A. Elbarbary, P. Ashjian, P. Benhaim, I.S. Chen, and M.H. Hedrick Multilineage cells from adipose tissue as gene delivery vehicles Hum. Gene Ther. 14 2003 59 66
77. S. Kern, H. Eichler, J. Stoeve, H. Kluter, and K. Bieback Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue Stem Cells 24 2006 1294 1301
78. R.H. Lee, S.C. Hsu, J. Munoz, J.S. Jung, N.R. Lee, R. Pochampally, and D.J. Prockop A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice Blood 107 2006 2153 2161
79. C.A. Gregory, H. Singh, A.S. Perry, and D.J. Prockop The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow J. Biol. Chem. 278 2003 28067 28078
80. S.B. Coffelt, F.C. Marini, K. Watson, K.J. Zwezdaryk, J.L. Dembinski, H.L. LaMarca, S.L. Tomchuck, K. Honer zu Bentrup, E.S. Danka, S.L. Henkle, and A.B. Scandurro The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells Proc. Natl. Acad. Sci. U. S. A. 106 2009 3806 3811
81. F. Djouad, P. Plence, C. Bony, P. Tropel, F. Apparailly, J. Sany, D. Noel, and C. Jorgensen Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals Blood 102 2003 3837 3844
82. A.E. Karnoub, A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, G.W. Bell, A.L. Richardson, K. Polyak, R. Tubo, and R.A. Weinberg Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449 2007 557 563
83. E.L. Spaeth, J.L. Dembinski, A.K. Sasser, K. Watson, A. Klopp, B. Hall, M. Andreeff, and F. Marini Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression PloS One 4 2009 e4992
84. W. Zhu, W. Xu, R. Jiang, H. Qian, M. Chen, J. Hu, W. Cao, C. Han, and Y. Chen Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo Exp. Mol. Pathol. 80 2006 267 274
85. A.Y. Khakoo, S. Pati, S.A. Anderson, W. Reid, M.F. Elshal, I.I. Rovira, A.T. Nguyen, D. Malide, C.A. Combs, G. Hall, J. Zhang, M. Raffeld, T.B. Rogers, W. Stetler-Stevenson, J.A. Frank, M. Reitz, and T. Finkel Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma J. Exp. Med. 203 2006 1235 1247
86. Y.R. Lu, Y. Yuan, X.J. Wang, L.L. Wei, Y.N. Chen, C. Cong, S.F. Li, D. Long, W.D. Tan, Y.Q. Mao, J. Zhang, Y.P. Li, and J.Q. Cheng The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo Cancer Biol. Ther. 7 2008 245 251
87. G.J. Maestroni, E. Hertens, and P. Galli Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice Cell. Mol. Life Sci.CMLS 55 1999 663 667
88. K. Nakamura, Y. Ito, Y. Kawano, K. Kurozumi, M. Kobune, H. Tsuda, A. Bizen, O. Honmou, Y. Niitsu, and H. Hamada Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model Gene Ther. 11 2004 1155 1164
89. L.B. Ohlsson, L. Varas, C. Kjellman, K. Edvardsen, and M. Lindvall Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix Exp. Mol. Pathol. 75 2003 248 255
90. K. Otsu, S. Das, S.D. Houser, S.K. Quadri, S. Bhattacharya, and J. Bhattacharya Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells Blood 113 2009 4197 4205
91. S. Komarova, Y. Kawakami, M.A. Stoff-Khalili, D.T. Curiel, and L. Pereboeva Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses Mol. Cancer Ther. 5 2006 755 766
92. C.A. Ramos, Z. Asgari, E. Liu, E. Yvon, H.E. Heslop, C.M. Rooney, M.K. Brenner, and G. Dotti An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies Stem Cells 28 2010 1107 1115
93. D. Rubio, J. Garcia-Castro, M.C. Martin, R. de la Fuente, J.C. Cigudosa, A.C. Lloyd, and A. Bernad Spontaneous human adult stem cell transformation Cancer Res. 65 2005 3035 3039
94. K. Pike-Overzet, M. van der Burg, G. Wagemaker, J.J. van Dongen, and F.J. Staal New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy Mol. Ther. 15 2007 1910 1916
95. S.C. Hung, W.P. Deng, W.K. Yang, R.S. Liu, C.C. Lee, T.C. Su, R.J. Lin, D.M. Yang, C.W. Chang, W.H. Chen, H.J. Wei, and J.G. Gelovani Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging Clin. Cancer Res. 11 2005 7749 7756
96. A. Nakamizo, F. Marini, T. Amano, A. Khan, M. Studeny, J. Gumin, J. Chen, S. Hentschel, G. Vecil, J. Dembinski, M. Andreeff, and F.F. Lang Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas Cancer Res. 65 2005 3307 3318
97. Y. Hu, K. Li, L. Wang, S. Yin, Z. Zhang, and Y. Zhang Pegylated immuno-lipopolyplexes: a novel non-viral gene delivery system for liver cancer therapy J. Control Release 144 2010 75 81
98. T.E. Meyerrose, M. Roberts, K.K. Ohlemiller, C.A. Vogler, L. Wirthlin, J.A. Nolta, and M.S. Sands Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease Stem Cells 26 2008 1713 1722